LENZ Therapeutics, Inc.
Moat Score — LENZ Therapeutics, Inc.
Total Moat Score
7 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | VIZZ is patent-protected as the first and only FDA-approved aceclidine-based presbyopia treatment, giving LENZ real but narrow intellectual-property and regulatory-exclusivity protection around a single molecule and indication. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | LENZ is a small commercial-stage company with no manufacturing scale or sourcing advantage; it has no evident cost edge over much larger eye-care incumbents like AbbVie or Bausch & Lomb. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | Because VIZZ is sold in the self-pay market with no insurer price negotiation, LENZ can set its own price, but consumer price sensitivity and multiple alternative drops (Vuity, Qlosi, generics) cap how much pricing power it can actually exercise. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in a prescription eye-drop business; prescribing and purchasing decisions are independent per patient and physician. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Once a patient and prescriber settle on a daily presbyopia drop there is modest routine stickiness, but switching to a competing drop like Vuity or Qlosi carries no meaningful clinical or financial friction. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | VIZZ currently has the aceclidine sub-category largely to itself, a narrow-market advantage, but this is already eroding as Yuvezzi and other aceclidine or next-generation programs (Tenpoint, AceVision, Vyluma) approach approval. |